A B S T R A CT Collagen stimulates the activation of phosphatidylinositol (PI)-specific phospholipase C (EC 3.1.4.10) in human platelets, as manifested by the disappearance of PI, the transient formation of diacylglycerol (DG), and release of myoinositol. Platelets exposed to collagen also form lysophosphatidylinositol (LPI). Maximum formation of DG occurs within 60 s of the addition of collagen and is in proportion to the concentration of collagen provided, up to 100 Mg!2 X 109 platelets/ml. Hydrolysis of PI, formation of DG, and release of arachidonic acid are all inhibited -68% by aspirin or indomethacin, both of which inhibit platelet cyclooxygenase. This inhibition is reversed by the product of cyclooxygenase activity, 15-hydroxy -9a,lla -peroxidoprosta -5,13 -dienoic acid (PGH2), or by the PGH2 analogue and agonist, U-46619. The counteracting effects of either PGH2 or the PGH2 analogue can be blocked, in turn, by a PGH2 antagonist, U-51605. Neither PGH2 nor its stable analogue is, by itself, an efficient stimulus for PI breakdown to DG and LPI in platelets. However, in conjunction with collagen, these agents synergistically promote the net breakdown of PI and the release of arachidonic acid in aspirin-treated platelets. Our findings thereby imply that PGH2 has an important role in regulating both the release of its precursor, arachidonic acid, and the metabolism of PI induced by collagen.
INTRODUCTION
Upon exposure to appropriate agonists, several varieties of secretory cells exhibit marked phospholipase C(PLC)'-mediated hydrolysis of phosphatidylinositol (PI) resulting in the generation of diacylglycerol (DG) (1) . The full nature of the function of such changes in cellular PI and DG is as yet unknown. There are indications that the metabolism of phosphatidylinositides via PLC may be a prerequisite for both the movement of Ca+2 within physiologically stimulated cells (1) (2) (3) and the release of arachidonic acid and subsequent formation of biologically active 15-hydroxy9a,1la-peroxidoprosta-5,13-dienoic acid (PGH2) and thromboxane A2 (TXA2) in platelets (4) (5) (6) . In the platelet, PI-specific PLC can be activated rapidly by thrombin (7), a stimulus for both secretion and the formation of PGH2 and TXA2 (8, 9) .
Our laboratory has demonstrated recently that the Ca+2 ionophore A23187 is an inefficient stimulus for PI-specific PLC, although phospholipase A is activated in platelets exposed to A23187 and TXA2 is formed (10) . This finding implies both that a general, passive flux in Ca+2 stores does not activate PLC and that PGH2/TXA2, formed in platelets in response to A23187, ' Abbreviations used in this paper: cAMP, cyclic AMP; ASA, acetylsalicylic acid; DG, diacylglycerol; HHT, 12L-hydroxy-5,8,10-heptadecatrienoic acid; HPLC, high performance liquid chromatography; INDO, indomethacin; LPI, lysophosphatidylinositol; PA, phosphatidic acid; PGH2, 15-hydroxy-9a,1la-peroxidoprosta-5,13-dienoic acid; PI, phosphatidylinositol; PLC, phospholipase C; TXA2, thromboxane A2.
is also a poor stimulus for this enzyme. It was clear from these studies that the factors regulating PI-specific PLC merited further examination.
Numerous investigations of platelet activation have centered upon the role of the potent arachidonic acid metabolites PGH2 and TXA2 in inducing aggregation and secretion (for a review, see MacIntyre, 11). However, no studies to date have examined the role of these agonists in controlling PI metabolism and their own production at the level of phospholipase. We have undertaken the present studies to evaluate the effect of PGH2/TXA2 upon the hydrolysis of PI and net release of arachidonic acid, and have chosen the physiologic platelet agonist collagen as a costimulus. Collagen is a potent inducer of PGH2/TXA2 formation and is particularly relevant to such studies in view of the known ability of cyclooxygenase inhibitors to reduce the prosecretory effects of collagen (12) . In this communication, we describe the initial metabolism of PI in platelets exposed to collagen in the presence or absence of several inhibitors of platelet function. We report a synergistic promotion by collagen and PGH2 of the PI response and arachidonic acid release, thereby implicating PGH2 in the regulation of phospholipases in platelets.
METHODS
Normal human platelet concentrates were obtained within 15 h of venipuncture and freed of any contaminating erythrocytes and buffy coat (7) . In some cases, blood was drawn in the laboratory from normal human volunteers (7) . Platelets were incubated in plasma at 37°C for 30 min with [5,6,8,9,11,12,14,15-3H] arachidonic acid (New England Nuclear, Boston, MA; 72 Ci/mmol, 50 nM) and washed (7) . Some platelet suspensions were incubated as well with 0.56 mM acetylsalicylic acid (ASA) (Sigma Chemical Co., St. Louis, MO) for 30 min before washing. Siliconized glassware was used in all studies.
Labeled platelets (final concentration 2 X 109 cells/ml) were suspended in an albumin-free modified Tyrode's buffer (13) Incubations were terminated by the addition of 3.75 vol chloroform/methanol (1:2) , and lipids were extracted by a modified Bligh and Dyer (10) procedure. Extracts were divided, and neutral lipids and phospholipids were resolved and quantitated as described previously (7, 10 (18), and columns were washed as described by Palmer (19) . All neutral lipids and nonacidic phospholipids and lysophospholipids came through the columns in fractions 1 and 2 (19) . Elution of acid phospholipids was achieved with a modification of Palmer's scheme (19) : PA was collected in vials containing 10 gl 8.5 M NH4 formate after being eluted from the columns with 6 . Two-dimensional chromatography of this fraction on silica-impregnated paper (20) confirmed that only PA and phosphatidylserine were present in this fraction. Lipids were detected under UV light with rhodamine spray (0.003%) and PA was eluted, successively, with 3 ml chloroform/methanol/2N HCI (25:15:2.5), 1 ml methanol, and 1 ml methanol/H20 (95:5). Eluates were assayed for phosphorus by the method of DuckChong (21 (25, 26) .
RESULTS
As shown in Fig. IA , hydrolysis of PI and formation of DG occurred in parallel in response to varied concentrations of collagen. Maximum changes were found in the presence of 100 ,ug/ml collagen/2 X 109 platelets/ml. As is the case when thrombin is the stimulus (7), triglyceride levels were unaltered upon exposure of platelets to collagen. Platelets achieved a maximum net hydrolysis of PI 2 min after exposure to collagen (Fig. 1B) . This degree of hydrolysis was equal to -8 nmol/2 X 109 platelets, or 25% of total PI. Release of arachidonic acid followed a similar pattern ( Figs. 2A  and B ) but exceeded the loss of PI. A transient formation of DG occurred within this period (Fig. iB) . DG reached its peak concentration within 60s, accounting for 10-15% of the PI hydrolyzed, approximately the percentage that accumulates in response to thrombin (7, 10) . Both the dose-response and kinetic data presented are consistent with the findings of Broekman et al. (27) , monitoring PI hydrolysis under comparable conditions. In response to a 60-s exposure to 100 ug/ml collagen, platelets formed 1.7 nmol TXB2/2 X 109 platelets, and an equivalent amount of 12L-hydroxy-5,8,10-heptadecatrienoic acid (HHT), as gauged by radioactivity ( (Fig. 3A) under conditions in which prostaglandin formation was blocked >99%. The net release of arachidonic acid was inhibited in parallel with the metabolism of PI and DG.
These findings are in contrast to those obtained with thrombin as a stimulus (5, 7, 10) . PGD2 (1 ,uM) inhibited TXB2 formation, arachidonic acid release, and PI metabolism (Fig. SA) Hydrolysis of PI and net release of arachidonic acid + metabolites were similarly unaffected, whereas formation of TXB2 was inhibited 98%. Fig. 4 illustrates the time course of PI and DG metabolism for platelets exposed to collagen in the presence and absence of ASA and 2 MM PGH2. ASA inhibited the PI response after both 60 and 120 s. The addition of PGH2 led to the normal metabolism of these two species, which was unaffected by the presence of 150 uM SQ22536. Since SQ22536 blocks the elevation of platelet cAMP by PGD2, it is clear that the slight contamination of PGH2 by PGD2 did not interfere with the platelet response to PGH2.
As shown in Table II , stimulation of platelets for 2 min with collagen led to the formation of LPI, accounting for -25% of the loss in PI. This species contained no [3H]arachidonic acid. Free myoinositol accounted for the majority of the change in PI. As has been observed to be the case for thrombin-stimulated platelets (22) , unhydrolyzed extracts accounted for most of the free myoinositol, implying that most of the myoinositol phosphate arising from the action of PLC had been digested by platelet phosphatases. PA, presumably derived via phosphorylation of DG, was observed in platelets exposed to collagen, as has been reported by Broekman et al. (27) . Treatment of platelets with aspirin before incubation with collagen inhibited the loss of PI, as we have noted already, as well as the formation of LPI, PA, and myoinositol. The addition of PGH2 to such platelets (resulting in the formation of 0.3 nmol TXB2/2.5 X 109 platelets) overcame much of the aspirin-induced inhibition. In all cases (data not shown), the specific activities of PI and PA were equivalent and did not themselves vary with incubation conditions. PGH2 added in the absence of collagen, but yielding an equal amount of TXB2 ±collagen, induced very little hydrolysis of PI and formation of PA, LPI, and myoinositol. However, PGH2/ TXA2 had a potentiating effect upon the stimulation of platelet lipid metabolism by collagen, an observation which is also represented in Fig. 5 . The formation of DG and release of arachidonic acid induced in aspirin-treated platelets exposed for 60 s to collagen were markedly enhanced by PGH2, as shown in Fig. 5 , upper curve. As an index of the access of platelets to PGH2 in the presence and absence of collagen, the formation of TXB2 was monitored by RIA, shown on the abscissa. PGH2 alone (lower curve) did not strongly promote the formation of DG or free arachidonic acid. This was also the case when varied concentrations of U-46619 were substituted for PGH2. The addition of PGH2 to collagen-exposed platelets incubated with aspirin (upper curve) led to significantly more formation of DG and free arachidonic acid than did the theoretical sum of collagen + ASA and PGH2 + ASA. The synergistic enhancement by collagen (100 gg/ml) and PGH2 (1 ,M) of DG production, PI hydrolysis, and the release of free arachidonic acid ranged in five experiments from 180-300% of the sum of the separate values. Similar, if not quite as marked, findings of synergism were attained with U-46619. These effects were unaltered by the addition of PGE2 or PGF2a at the concentrations found in preparations of PGH2. As little as 0.8 ,uM PGH2/2 X 109 platelets was sufficient both to achieve a maximum synergistic effect and to overcome the inhibitory effects of ASA on collagen-initiated PI metabolism. This Diminno et al. (31) , who have noted e metabolism that, whereas the PGH2 analogue U-46619 (0.9-12 acid from PI AM) induces platelet aggregation, it does not lead to )sed to colla-prostaglandin production. We have found that araDf the hydro-chidonic acid is not released in response to U-46619 also detected or PGH2. Neither PI-specific PLC nor phospholipase for -25% of A2 is activated under these conditions. iis species in Finally, elevation of the platelet's content of cAMP lore has been effectively blocks PI metabolism and arachidonic acid med directly liberation, including that portion which is not depen-;tivity which dent upon PGH2 formation. PGD2 inhibits the hydroin our labo-lysis of PI, the release of arachidonic acid, and the at LPI could formation of TXB2/HHT. PGD2 does not appear to achieve this general inhibition by depressing cyclooxygenase activity, since the response of aspirin-treated d0 platelets to collagen is inhibited 90% by PGD2. The (32) (33) (34) . The PI response in thrombin-stimulated platelets (which is not dependent on cyclooxygenase activity) is also inhibited by cAMP (7) . Thus, whether collagen or thrombin is the stimulus, cAMP exerts its major effects before prostaglandin formation. The major findings reported here have some interesting clinical and pathophysiological implications. We have observed that platelets responding to collagen normally produce four to five times more PGH2 than they need as a synergistic cohort. Thus, platelets with below normal cyclooxygenase activity due either to partial inactivation or deficienicy of this enzyme should nonetheless display a normal PI response and mobilize arachidonic acid when exposed to collagen, provided that they can synthesize at least 0.8 uM PGH2/2 X 109 cells. The role of PGH2 as a potent synergistic promoter, but not initiator, of PI breakdown and arachidonate release implies that platelets interacting with the intima of vessel walls should release the most arachidonic acid and form the most prostaglandin where it is needed, at the site of injury. Yet, the PGH2 and TXA2 diffusing to platelets more distant from exposed intima should not lead endlessly to more prostaglandin formation.
It is clear from this and our previous study (10) that not all platelet agonists activate PLC. The role fulfilled by the hydrolysis of PI to DG in platelets responding to thrombin or collagen may be duplicated by the Ca+2 ionophore A23187 or by PGH2, thereby obviating the need for PLC activation to achieve the secretory response. Such a role could be the promotion of a flux in Ca 2. Michell (1, 2) has noted that the hydrolysis of PI by PLC is directly coupled in many cell types to receptor stimulation and has proposed that this event leads to the transport of Ca 2. PI-PLC in this model would have a Ca+2-gating function. If PI-PLC activation is required for movement of Ca+2 to occur, it is reasonable to expect that a Ca+2 flux should not of itself activate PI-PLC. PI-PLC is indeed dependent upon Ca+2 (7, 35) , but there may well be sufficient membrane-bound Ca+2 available in quiescent platelets to permit the initial activity of PI-PLC that occurs in response to collagen. However, amplification by PGH2 of the initial "receptor--activated breakdown of PI by PLC might still take place. Cyclic AMP may act to interfere with the coupling of platelet PI-PLC to the thrombin and collagen "receptors,'" or to promote the resynthesis of PI, or both.
